{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T18:49:25Z","timestamp":1775760565834,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key R&D Program of Zhejiang","award":["No.2023C03073"],"award-info":[{"award-number":["No.2023C03073"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972374"],"award-info":[{"award-number":["81972374"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multi-parametric magnetic resonance imaging (mpMRI) is a diagnostic tool used for screening, localizing, and staging prostate cancer. Patients with Prostate Imaging Reporting and Data System (PI-RADS) score of 1 and 2 are considered negative mpMRI, with a lower likelihood of detecting clinically significant prostate cancer (csPCa). However, relying solely on mpMRI is insufficient to completely exclude csPCa, necessitating further stratification of csPCa patients using biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective study was conducted on mpMRI-negative patients who underwent prostate biopsy at the First Affiliated Hospital of Zhejiang University from January 2022 to June 2023. A total of 607 patients were included based on inclusion and exclusion criteria. Univariate and multivariate logistic regression analysis were performed to identify risk factors for diagnosing csPCa in patients with negative mpMRI. Receiver Operating Characteristic (ROC) curves were plotted to compare the discriminatory ability of different Prostate-Specific Antigen Density (PSAD) cutoff values for csPCa.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 607 patients with negative mpMRI, 73 patients were diagnosed with csPCa. In univariate logistic regression analysis, age, PSA, f\/tPSA, prostate volume, and PSAD were all associated with diagnosing csPCa in patients with negative mpMRI (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), with PSAD being the most accurate predictor. In multivariate logistic regression analysis, f\/tPSA, age, and PSAD were independent predictors of csPCa (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). PSAD cutoff value of 0.20 ng\/ml\/ml has better discriminatory ability for predicting csPCa and is a significant risk factor for csPCa in multivariate analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Age, f\/tPSA, and PSAD are independent predictors of diagnosing csPCa in patients with negative mpMRI. It is suggested that patients with negative mpMRI and PSAD less than 0.20 ng\/ml\/ml could avoid prostate biopsy, as a PSAD cutoff value of 0.20 ng\/ml\/ml has better diagnostic performance than the traditional cutoff value of 0.15 ng\/ml\/ml.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-024-03420-7","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T02:01:28Z","timestamp":1716861688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China"],"prefix":"10.1186","volume":"22","author":[{"given":"Shen","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wubin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiafeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sida","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"3420_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71:209\u201349.","DOI":"10.3322\/caac.21660"},{"key":"3420_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"3420_CR3","doi-asserted-by":"crossref","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R et al. Cancer incidence and mortality in China, 2022. Journal of the National Cancer Center [Internet]. 2024 [cited 2024 Feb 21]; https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2667005424000061.","DOI":"10.1016\/j.jncc.2024.01.006"},{"key":"3420_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bju.14361","volume":"122","author":"M Brizmohun Appayya","year":"2018","unstructured":"Brizmohun Appayya M, Adshead J, Ahmed HU, Allen C, Bainbridge A, Barrett T, et al. National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting. BJU Int. 2018;122:13\u201325.","journal-title":"BJU Int"},{"key":"3420_CR5","doi-asserted-by":"crossref","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Eur Urol. 2019;76:340\u201351. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.","DOI":"10.1016\/j.eururo.2019.02.033"},{"key":"3420_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, D\u2019Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:479\u2013505.","journal-title":"J Natl Compr Canc Netw"},{"key":"3420_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","volume":"78","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen NJ, Omer A, Harriss E, Davies L, Kasivisvanathan V, Punwani S, et al. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the detection of clinically significant prostate Cancer in the prostate imaging reporting and Data System era: a systematic review and Meta-analysis. Eur Urol. 2020;78:402\u201314.","journal-title":"Eur Urol"},{"key":"3420_CR8","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/j.clgc.2020.04.006","volume":"18","author":"M Roscigno","year":"2020","unstructured":"Roscigno M, Stabile A, Lughezzani G, Pepe P, Galosi AB, Naselli A, et al. The Use of Multiparametric Magnetic Resonance Imaging for follow-up of patients included in active surveillance protocol. Can PSA Density discriminate patients at different risk of reclassification? Clin Genitourin Cancer. 2020;18:e698\u2013704.","journal-title":"Clin Genitourin Cancer"},{"key":"3420_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.juro.2017.03.130","volume":"198","author":"FA Distler","year":"2017","unstructured":"Distler FA, Radtke JP, Bonekamp D, Kesch C, Schlemmer H-P, Wieczorek K, et al. The value of PSA Density in Combination with PI-RADS\u2122 for the accuracy of prostate Cancer prediction. J Urol. 2017;198:575\u201382.","journal-title":"J Urol"},{"key":"3420_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4103\/aja.aja_19_18","volume":"20","author":"X-Y Zeng","year":"2018","unstructured":"Zeng X-Y, Liu C, Liu S-L, Wang Z-X, Yu K, Feng C-X, et al. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment. Asian J Androl. 2018;20:459.","journal-title":"Asian J Androl"},{"key":"3420_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4103\/aja202220","volume":"24","author":"L Yang","year":"2022","unstructured":"Yang L, Wei Q, Zhang C-C, Tu X, Lin T-H, Cai D-M, et al. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-na\u00efve men: clinical outcomes from a high-volume center in China. Asian J Androl. 2022;24:615.","journal-title":"Asian J Androl"},{"key":"3420_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.euf.2022.10.002","volume":"9","author":"F Pellegrino","year":"2023","unstructured":"Pellegrino F, Tin AL, Martini A, Vertosick EA, Porwal SP, Stabile A, et al. Prostate-specific Antigen Density Cutoff of 0.15 ng\/ml\/cc to propose prostate biopsies to patients with negative magnetic resonance imaging: efficient threshold or legacy of the past? Eur Urol Focus. 2023;9:291\u20137.","journal-title":"Eur Urol Focus"},{"key":"3420_CR13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.euo.2022.03.007","volume":"5","author":"HB Luiting","year":"2022","unstructured":"Luiting HB, Remmers S, Boev\u00e9 ER, Valdagni R, Chiu PK, Semjonow A, et al. A Multivariable Approach using magnetic resonance imaging to avoid a protocol-based prostate biopsy in men on active surveillance for prostate Cancer\u2014data from the International Multicenter prospective PRIAS study. Eur Urol Oncol. 2022;5:651\u20138.","journal-title":"Eur Urol Oncol"},{"key":"3420_CR14","first-page":"725","volume":"205","author":"J Buisset","year":"2021","unstructured":"Buisset J, Norris JM, Puech P, Leroy X, Ramdane N, Drumez E, et al. Negative Prebiopsy Magnetic Resonance Imaging and risk of significant prostate Cancer: baseline and long-term followup results. Eur Urol. 2021;205:725\u201331.","journal-title":"Eur Urol"},{"key":"3420_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.eururo.2022.07.022","volume":"82","author":"M Peters","year":"2022","unstructured":"Peters M, Eldred-Evans D, Kurver P, Falagario UG, Connor MJ, Shah TT, et al. Predicting the need for Biopsy to detect clinically significant prostate Cancer in patients with a magnetic resonance imaging\u2013detected prostate imaging reporting and data System\/Likert\u2009\u2265\u20093 lesion: development and multinational external validation of the Imperial Rapid Access to Prostate Imaging and diagnosis risk score. Eur Urol. 2022;82:559\u201368.","journal-title":"Eur Urol"},{"key":"3420_CR16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2214\/AJR.20.22784","volume":"215","author":"HY Ma","year":"2020","unstructured":"Ma HY, Ahmed FS, Luk L, Martina LAP, Wenske S, Shaish H. The negative predictive value of a PI-RADS version 2 score of 1 on prostate MRI and the factors Associated with a false-negative MRI study. Am J Roentgenol. 2020;215:667\u201372.","journal-title":"Am J Roentgenol"},{"key":"3420_CR17","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618\u201329.","journal-title":"Eur Urol"},{"key":"3420_CR18","doi-asserted-by":"crossref","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40:244\u201352.","DOI":"10.1097\/PAS.0000000000000530"},{"key":"3420_CR19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest M, Cornel E, Isra\u00ebl B, Hendriks R, Padhani AR, Hoogenboom M, et al. Head-to-head comparison of Transrectal Ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided Biopsy in Biopsy-na\u00efve men with elevated prostate-specific Antigen: a large prospective Multicenter Clinical Study. Eur Urol. 2019;75:570\u20138.","journal-title":"Eur Urol"},{"key":"3420_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","volume":"20","author":"O Rouvi\u00e8re","year":"2019","unstructured":"Rouvi\u00e8re O, Puech P, Renard-Penna R, Claudon M, Roy C, M\u00e8ge-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20:100\u20139.","journal-title":"Lancet Oncol"},{"key":"3420_CR21","first-page":"CD012663","volume":"4","author":"F-JH Drost","year":"2019","unstructured":"Drost F-JH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4:CD012663.","journal-title":"Cochrane Database Syst Rev"},{"key":"3420_CR22","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or standard biopsy for prostate-Cancer diagnosis. N Engl J Med. 2018;378:1767\u201377.","journal-title":"N Engl J Med"},{"key":"3420_CR23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The Additive Diagnostic Value of prostate-specific membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the diagnosis of prostate Cancer (PRIMARY): a prospective Multicentre Study. Eur Urol. 2021;80:682\u20139.","journal-title":"Eur Urol"},{"key":"3420_CR24","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.21873\/anticanres.15785","volume":"42","author":"P PEPE","year":"2022","unstructured":"PEPE P, PEPE L, COSENTINO S, IPPOLITO M, PENNISI M. Detection rate of 68Ga-PSMA PET\/CT vs. mpMRI targeted biopsy for clinically significant prostate Cancer. Anticancer Res. 2022;42:3011\u20135.","journal-title":"Anticancer Res"},{"key":"3420_CR25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.clgc.2023.06.007","volume":"21","author":"P Pepe","year":"2023","unstructured":"Pepe P, Pennisi M. Targeted biopsy in men high risk for prostate Cancer: 68Ga-PSMA PET\/CT Versus mpMRI. Clin Genitourin Cancer. 2023;21:639\u201342.","journal-title":"Clin Genitourin Cancer"},{"key":"3420_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bju.14049","volume":"122","author":"NL Hansen","year":"2018","unstructured":"Hansen NL, Barrett T, Kesch C, Pepdjonovic L, Bonekamp D, O\u2019Sullivan R, et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-na\u00efve men with suspicion of prostate cancer. BJU Int. 2018;122:40\u20139.","journal-title":"BJU Int"},{"key":"3420_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4103\/1008-682X.167103","volume":"19","author":"J Teoh","year":"2017","unstructured":"Teoh J, Yuen S, Tsu J, Wong C, Ho B, Ng A, et al. The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men. Asian J Androl. 2017;19:113.","journal-title":"Asian J Androl"},{"key":"3420_CR28","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00432-008-0400-8","volume":"134","author":"X-Y Zheng","year":"2008","unstructured":"Zheng X-Y, Xie L-P, Wang Y-Y, Ding W, Yang K, Shen H-F, et al. The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4\u201310 ng\/mL. J Cancer Res Clin Oncol. 2008;134:1207\u201310.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3420_CR29","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.7314\/APJCP.2012.13.11.5529","volume":"13","author":"X-Y Zheng","year":"2012","unstructured":"Zheng X-Y, Zhang P, Xie L-P, You Q-H, Cai B-S, Qin J. Prostate-specific Antigen velocity (PSAV) and PSAV per initial volume (PSAVD) for early detection of prostate Cancer in Chinese men. Asian Pac J Cancer Prev. 2012;13:5529\u201333.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3420_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.eururo.2020.04.029","volume":"78","author":"JM Norris","year":"2020","unstructured":"Norris JM, Carmona Echeverria LM, Bott SRJ, Brown LC, Burns-Cox N, Dudderidge T, et al. What type of prostate Cancer is systematically overlooked by Multiparametric Magnetic Resonance Imaging? An analysis from the PROMIS Cohort. Eur Urol. 2020;78:163\u201370.","journal-title":"Eur Urol"},{"key":"3420_CR31","first-page":"886","volume":"27","author":"ES-L Zhang","year":"2021","unstructured":"Zhang ES-L, Wu Y-X. [Risk factors for prostate cancer in male patients with MRI-negative and PSA-abnormal findings]. Zhonghua Nan Ke Xue. 2021;27:886\u201391.","journal-title":"Zhonghua Nan Ke Xue"},{"key":"3420_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","volume":"2","author":"R Zheng","year":"2022","unstructured":"Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2:1\u20139.","journal-title":"J Natl Cancer Cent"},{"key":"3420_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000358494","volume":"93","author":"P Pepe","year":"2014","unstructured":"Pepe P, Dibenedetto G, Pennisi M, Fraggetta F, Colecchia M, Aragona F. Detection rate of anterior prostate Cancer in 226 patients submitted to initial and repeat Transperineal Biopsy. Urol Int. 2014;93:189\u201392.","journal-title":"Urol Int"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03420-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03420-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03420-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T02:04:24Z","timestamp":1716861864000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03420-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3420"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03420-7","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of The First Affiliated Hospital of Zhejiang University School of Medicine. The ethics committee of The First Affiliated Hospital of Zhejiang University School of Medicine waived the need for Informed Consent due to the retrospective nature of the study. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}